Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDV-2000 CYP3A4 Induction Study
NCT05694533Phase 1Completed
- Sponsor
- Indivior
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C4X3256 in opioid use disorder (OUD), sponsored by Indivior. Primary endpoints: Maximum Observed Plasma Concentration of Midazolam and 1-hydroxymidazolam at Day 15, Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity of Midazolam and 1-hydroxymidazolam at Day 15 and 1 more. Started Mar 2023; status: completed.
02
Drugs
C4X3256
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05694533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694533.